Investor Area

Home / Investor Area / Nomura Update “CUV’s statistically significant EPP results”

Nomura Update “CUV’s statistically significant EPP results”

CLINUVEL demonstrates positive treatment effect of afamelanotide in US Phase II study

Analyses from US confirmatory study demonstrated a dramatic improvement in Quality of Life from afamelanotide 16mg in the orphan disease erythropoietic protoporphyria (EPP).